Bausch + Lomb Corporation $BLCO Shares Acquired by Allianz Asset Management GmbH

Allianz Asset Management GmbH lifted its stake in shares of Bausch + Lomb Corporation (NYSE:BLCO) by 136.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 769,000 shares of the company’s stock after buying an additional 444,000 shares during the period. Allianz Asset Management GmbH’s holdings in Bausch + Lomb were worth $10,005,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BLCO. Deutsche Bank AG acquired a new stake in shares of Bausch + Lomb during the first quarter worth $50,750,000. Alberta Investment Management Corp lifted its stake in shares of Bausch + Lomb by 8.6% during the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock worth $47,360,000 after buying an additional 258,000 shares during the period. Clearline Capital LP lifted its stake in shares of Bausch + Lomb by 38.2% during the first quarter. Clearline Capital LP now owns 893,790 shares of the company’s stock worth $12,960,000 after buying an additional 247,149 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Bausch + Lomb by 428.7% during the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock worth $4,345,000 after buying an additional 242,993 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Bausch + Lomb during the first quarter worth $2,119,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BLCO. Evercore ISI lifted their price objective on shares of Bausch + Lomb from $16.50 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. The Goldman Sachs Group initiated coverage on shares of Bausch + Lomb in a research report on Wednesday, October 1st. They set a “neutral” rating and a $16.00 target price for the company. Zacks Research upgraded shares of Bausch + Lomb to a “hold” rating in a research report on Tuesday, August 12th. Morgan Stanley boosted their target price on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Finally, Wells Fargo & Company boosted their target price on shares of Bausch + Lomb from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $15.70.

Bausch + Lomb Trading Down 0.6%

NYSE BLCO opened at $15.66 on Wednesday. The company has a fifty day moving average of $14.86 and a 200 day moving average of $13.37. The company has a market capitalization of $5.55 billion, a PE ratio of -20.08, a P/E/G ratio of 1.72 and a beta of 0.63. Bausch + Lomb Corporation has a 1 year low of $10.45 and a 1 year high of $20.94. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.55 and a quick ratio of 0.98.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. Research analysts forecast that Bausch + Lomb Corporation will post 0.74 earnings per share for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.